Synopsis:
Torrent Pharma shares jumped over 6 percent after the company reported strong Q2 FY26 earnings, delivering 32 percent YoY net profit growth with broad based revenue expansion across India, US, Brazil and other markets.
The shares of this leading Indian pharmaceutical company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations is now in the focus after reporting its Q2 results with net profit growth of 32 percent year-on-year.
With market capitalization of Rs. 1,27,994 cr, the shares of Torrent Pharmaceuticals Ltd are currently trading at Rs. 3,782 per share, increasing more than 6 percent in today’s market session making a high of Rs. 3,809.80, from its previous close of Rs. 3,580 per share.
YoY performance
Torrent Pharma posted a strong performance in Q2 FY26 with healthy double-digit YoY growth across key metrics. Sales grew 14 percent to Rs. 3,302 crore in Q2FY26 from Rs. 2,889 crore in Q2FY25, with EBITDA rising 15 percent YoY to Rs. 1,083 crore from Rs. 939 crore. Net profit saw a sharp 32 percent YoY jump to Rs. 591 crore compared to Rs. 453 crore, while EPS improved 30 percent YoY to Rs. 17.46 from Rs. 13.39.
QoQ performance
On a QoQ basis, revenue improved moderately from Rs. 3,178 crore in Q1 FY26 to Rs. 3,302 crore in Q2 FY26. EBITDA increased 5 percent from Rs. 1,032 crore to Rs. 1,083 crore QoQ. Net profit improved 8 percent from Rs. 548 crore last quarter to Rs. 591 crore this quarter.
Torrent Pharma reported revenues of Rs. 3,302 crore in Q2 FY26, up 14 percent YoY. India continued to remain the largest contributor with Rs. 1,820 crore, growing 12 percent YoY.
The US business posted strong growth of 26 percent to Rs. 337 crore, while Brazil also delivered healthy traction with a 21 percent rise to Rs. 318 crore. Germany was steady with 5 percent growth and the ‘Others’ markets collectively grew 20 percent YoY to Rs. 524 crore.
Torrent Pharmaceuticals Ltd is a leading Indian pharma company with strong presence in chronic therapies such as cardio, CNS, GI and diabetes. The company has a well established branded generic franchise in India and meaningful global presence across Brazil, Germany and the U.S. Torrent focuses on specialty led portfolio, quality compliance, differentiated products and steady expansion in high margin therapies.
The company delivers strong return ratios with ROCE at 27 percent and ROE at 26.5 percent. It also maintains a healthy dividend payout track record at around 57.9 percent.
Written by Manideep Appana
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
